Related Experiment Videos
Experience with use of recombinant activated factor VII
F Divanon1, C Hecquard, A Borel-Derlon
1Department of Pharmacy, Centre Hospitalier Universitaire, Avenue Côte de Nacre, Caen Cedex, France. divanon-f@chu-caen.fr
Journal of Clinical Pharmacy and Therapeutics
|April 27, 2002
Summary
Recombinant activated factor VII (rFVIIa) effectively manages bleeding in hemophilia patients with inhibitors. This treatment proved safe and successful across various hemorrhagic conditions, including surgical and non-surgical cases.
Area of Science:
- Hematology
- Pharmacology
Background:
- Recombinant activated factor VII (rFVIIa) is a treatment for hemophilia patients with inhibitors to factor VIII (FVIII) or factor IX (FIX).
- Alloantibodies (inhibitors) pose challenges in managing bleeding episodes in hemophilia.
Observation:
- This study reports the successful use of rFVIIa in five distinct clinical scenarios.
- These included surgical bleeding in a hemophilia A patient and non-surgical hemorrhages in patients with hemophilia A, acquired hemophilia, severe factor V deficiency, and pseudo-acquired hemophilia.
Findings:
- rFVIIa demonstrated effectiveness in controlling bleeding across all reported cases.
- The treatment was also found to be safe, with no adverse events noted.
Implications:
- rFVIIa is a valuable therapeutic option for patients with inhibitors to FVIII or FIX.
- Further cost-effectiveness analysis is recommended due to the high cost of rFVIIa treatment.